According to the latest market research study by Technavio, the global prostate biopsy market is expected to grow at a CAGR of close to 10% during the forecast period 2017 to 2021.
This report by Technavio provides an in-depth analysis of the global prostate biopsy market regarding revenue and emerging market trends. The report also includes an up-to-date analysis and forecasts for various market segments and all geographical regions.
Technavio research analysts categorize the market based on the end-user type
Click here to request a free sample of this report
The top three revenue contributing end-user segments are discussed below:
Hospitals: Hospitals, especially the big ones have the state-of-the-art medical infrastructure to cater to the needs of people. In these hospitals, diagnosis and monitoring of chronic diseases are conducted in outpatient settings. The surgeries are conducted in surgical rooms with special operating rooms.
“Prostate biopsy systems are largely performed in big hospitals. The capital investment for prostate biopsies in such institutions is mainly for ultrasound and MRI image guiding machines that are used in these hospitals as supportive devices for performing prostate cancer diagnosis,” says Sapna Jha, a lead analyst at Technavio for research on orthopedics and medical devices.
ASCs: ASCs refers to modern healthcare facilities that are aimed to provide same-day medical assistance, including diagnostic and preventive procedures. These centers have transformed the outpatient experience for millions of individuals in the US by providing convenient facilities, as an alternative to hospital-based outpatient procedures. These centers are engaged in maintaining a strong record of accomplishment of quality care and positive patient outcomes. Urologists perform prostate needle-based biopsies to remove prostate tissue from a prostate gland under general anesthesia. The number of prostate needle biopsies performed in ASCs is rising at a significant rate compared to hospitals, especially in developed countries.
Diagnostic centers: The amount of prostate cancer diagnosis is more in diagnostic centers compared to hospitals. They can be large, medium, or small-sized diagnostic centers based on the volume of analysis or imaging performed. Large-sized diagnostic centers are linked with many hospitals and provide cost-effective diagnostic results to improve patient care. These centers conduct tests using advanced equipment and electronically transmit the results to the hospital, which helps reduce medical expenses and minimize the duration of result delivery. These diagnostic centers have skilled resources who can perform prostate biopsies.
Ask an analyst to know more about this report
The top vendors operating in the global prostate biopsy market are:
- C.R. Bard
- Cook Medical
- Endomed Systems
- SOMATEX Medical Technologies
- Biomedical
The other prominent vendors in the market include Amecath, AprioMed, Argon Medical Devices, Biopsybell, Boston Scientific, Exosome Diagnostics, MDNA Life Sciences, MDxHealth, Möller Medical, Pathway Genomics, Predicine, Sterylab, TSK Laboratory Europe, UroMed, and Urotech.
A more detailed analysis is available in the Technavio market research report titled, ‘Global Prostate Biopsy Market 2017-2021’. Technavio also customizes reports by other regions and specific segments upon request.
Other related reports:
- Global Biopsy Devices Market 2016-2020
- Global Surgical Navigation Systems Market 2016-2020
- Global Cancer Diagnostic Devices Market 2016-2020
To read more press releases – click here
